Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (Nasdaq: SILO) has successfully closed an underwritten public offering of 1,150,000 shares of common stock at $5.00 per share, raising gross proceeds of $5.75 million. This offering includes the exercise of an over-allotment option for 150,000 additional shares. The funds will be primarily used for product development, marketing, and working capital, with a potential portion allocated for acquisitions. The company began trading on the Nasdaq on September 27, 2022.
Silo Pharma announced its common stock will commence trading on Nasdaq under the symbol SILO on September 27, 2022. The company has priced an underwritten public offering of 1,000,000 shares at $5.00 per share, aiming to raise $5 million before expenses. Proceeds will fund product development, marketing, and working capital, with potential use for acquiring complementary businesses. The transaction is expected to close by September 29, 2022. Laidlaw & Company is the sole book-running manager for this offering.
Silo Pharma, Inc. (OTCQB: SILO) announced a 1-for-50 reverse stock split effective September 15, 2022. This action is part of the company's strategy to qualify for listing on The Nasdaq Capital Market. Following the reverse split, approximately 1,987,906 shares will be outstanding. The reverse stock split aims to help Silo Pharma meet the minimum share price requirement for Nasdaq. The temporary trading symbol will change to "SILOD" until the Nasdaq listing is finalized.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from an animal study demonstrating its topical Ketamine formulation's effectiveness in reducing neuropathic nerve pain. The study showed a significant reduction in both allodynia and hyperalgesia using its patented delivery system in partnership with Zylo Therapeutics. Notably, day seven and day nine evaluations showed no erythema or swelling, indicating a favorable safety profile, which is promising for upcoming toxicology studies. CEO Eric Weisblum emphasized the potential benefits for patients with Fibromyalgia and Rheumatoid Arthritis.
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from animal studies demonstrating the effectiveness and reduced toxicity of its novel liposomes using a subcutaneous delivery method for anti-arthritic agents. CEO Eric Weisblum stated that this method is well-suited for targeted drug delivery, enhancing efficacy and minimizing systemic toxicity. Previous studies with intravenous injections showed promising results, and the new findings indicate that subcutaneous administration is comparable in performance, with potential for even greater effectiveness.
Silo Pharma (OTCQB: SILO) announced an expansion of its Commercial Evaluation License Agreement with the University of Maryland Baltimore for next-generation Liposomal Peptides aimed at treating autoimmune diseases. Positive results from pre-clinical tests in arthritis models were highlighted, showing significant therapeutic effects of specific peptides (NQR and RGD). The global market for autoimmune disease therapeutics is projected to exceed $150 billion by 2025, bolstering Silo's prospects for growth and investment potential.
Silo Pharma, Inc. (OTCQB: SILO) has successfully dosed patients with Parkinson's disease in a study in collaboration with the University of California San Francisco (UCSF). This research aims to examine the effects of psilocybin on inflammatory markers in these patients. The study is part of UCSF's Translational Psychedelic Research (TrPR) Program, which investigates the impact of psychedelics on brain health. CEO Eric Weisblum highlighted this milestone, expressing optimism about the forthcoming results and future patient cohorts.
Silo Pharma (OTCQB: SILO) announced the production of its first batch of liposomes for a preclinical study targeting anti-arthritic activity through its SPU-21 compound. This study will be conducted by Frontage Laboratories. The CEO, Eric Weisblum, emphasized that this development advances the research on SPU-21, which has potential applications in autoimmune diseases like rheumatoid arthritis (RA). The liposomes are designed to enhance drug delivery and effectiveness while reducing toxicity.
Silo Pharma, Inc. (OTCQB: SILO) has partnered with Frontage Laboratories to advance its Central Nervous System Peptide, SPU-16, and Joint Homing Peptide, SPU-21, technologies toward clinical application. This agreement aims to facilitate a Pharmacokinetic Study in animals, which will analyze doses and plasma samples. CEO Eric Weisblum highlighted the potential of these peptides to enhance therapeutic effects while reducing systemic toxicity, with applications in treating central nervous system and autoimmune diseases.
Silo Pharma, a developmental stage biopharmaceutical company, announced its partnership with IBN to enhance corporate communications. This collaboration aims to leverage IBN's extensive investor distribution network to raise awareness for Silo's innovative therapeutic solutions targeting PTSD, Alzheimer’s, and other neurological disorders. Silo has established research agreements with leading universities, including studies on ketamine and psilocybin for Parkinson’s disease and inflammation. This partnership underscores Silo's commitment to advancing medical research and developing transformative treatments.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
